Market Cap | 334.82M | P/E | - | EPS this Y | 27.80% | Ern Qtrly Grth | - |
Income | -130.41M | Forward P/E | -2.40 | EPS next Y | 1.60% | 50D Avg Chg | -2.00% |
Sales | 5.76M | PEG | - | EPS past 5Y | - | 200D Avg Chg | -6.00% |
Dividend | N/A | Price/Book | 1.37 | EPS next 5Y | - | 52W High Chg | -38.00% |
Recommedations | 1.60 | Quick Ratio | 6.42 | Shares Outstanding | 61.37M | 52W Low Chg | 54.00% |
Insider Own | 0.71% | ROA | -27.99% | Shares Float | 34.90M | Beta | 1.44 |
Inst Own | 89.57% | ROE | -59.51% | Shares Shorted/Prior | 2.79M/2.86M | Price | 6.78 |
Gross Margin | 100.00% | Profit Margin | - | Avg. Volume | 149,540 | Target Price | 15.83 |
Oper. Margin | -695.25% | Earnings Date | - | Volume | 83,496 | Change | -1.74% |
Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.
Wells Fargo | Overweight | Aug 12, 24 |
Piper Sandler | Overweight | Jun 28, 24 |
Wedbush | Outperform | May 22, 24 |
Wedbush | Outperform | Feb 15, 24 |
JP Morgan | Overweight | Oct 19, 23 |
Credit Suisse | Neutral | Aug 11, 23 |
Credit Suisse | Neutral | May 12, 23 |
Credit Suisse | Neutral | Mar 17, 23 |
Wells Fargo | Overweight | Jan 3, 23 |